Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
Isla McKerrow Johnson, Evandro D. Bezerra, Faiqa Farrukh, Kristen McCullough, Aref Al‐Kali, Hassan B. Alkhateeb, Kebede H. Begna, Mark R. Litzow, William J. Hogan, Mithun Vinod Shah, Mrinal M. Patnaik, Ayalew Tefferi, Naseema Gangat
Abstract
Venetoclax, a small-molecule inhibitor of B-cell lymphoma-2, in combination with the hypomethylating agents (HMA) azacitidine or decitabine, is FDA-approved for elderly/unfit patients with acute myeloid leukemia (AML). It is frequently used both in the upfront and relapsed/refractory setting based on superior efficacy and improved survival of the combination regimen compared with HMA alone.
Topics & Concepts
VenetoclaxHypomethylating agentMyeloid leukemiaMedicineAzacitidineMyeloidInternal medicineLeukemiaOncologyMyelodysplastic syndromesBiologyGeneticsBone marrowDNA methylationGeneChronic lymphocytic leukemiaGene expressionAcute Myeloid Leukemia ResearchBlood disorders and treatmentsVascular Tumors and Angiosarcomas